Lantern Pharma INC Schedule 13D activist filings

Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.

NASDAQ

16 Apr 2026

LTRN

SCHEDULE: Bios Equity Partners Updates Lantern Pharma Stake

Bios Equity Partners and associated entities have filed an amendment to their Schedule 13D regarding their beneficial ownership in Lantern Pharma Inc.

NASDAQ

23 Feb 2026

LTRN

Lantern Pharma INC

SCHEDULE: Bios Entities Update Lantern Pharma Stake to 8.58%

Bios Capital Management and related entities report a combined 8.58% beneficial ownership in Lantern Pharma Inc. common stock.

NASDAQ

14 Jun 2025

LTRN

Lantern Pharma INC

SCHEDULE 13D/A: Bios Equity Group Reduces Stake in Lantern Pharma, Selling Over 157,000 Shares

A group of investment entities and individuals, including Bios Equity Partners and Cavu Management, have significantly reduced their beneficial ownership in Lantern Pharma Inc. through a series of open market sales.